AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03228654 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unipolar Electrocautery sealing of vessels
Description: 1. Vaginal walls are incised by monoplar current (40 W)~2. A curved Bulldog Clamp is applied just 0.5 cm lateral to the uterine border along its attachements all through the pedicles. Then unipolar electrocautery (40 W) is applied to the pedicles along the lateral border of the uterus medial to the artery with maximum thickness 1 cm.~3. uterine vessels are individually secured.~4. Conventional volume reduction maneuvers are used as associated procedures in cases of large uteri to create the parauterine space to approach the lateral attachements.
Study NCT03228654 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Purohit technique for vaginal hysterectomy
Description: using Bipolar electrosurgical sealing of vessels during vaginal hysterctomy
Study NCT03976778 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Training program for family physicians on well-child care for children under-5 years
Description: The researchers designed this intervention, which consisted of 3 repeated workshops, every workshop had held for 2 days, one day per week, the number of attendants was appropriate/workshop (10 - 15).
Study NCT00168714 — intervention group
Intervention type: DRUG
Intervention: BG9418 (interferon beta-1a)
Description: Exposure to Avonex during pregnancy
Study NCT02652715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02652715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02652715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02652715 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Salvia hispanica Seed
Description: Given PO
Study NCT02370199 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 670 nm light
Description: 670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.
Study NCT02370199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octafluropropane
Description: Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.
Study NCT00926952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylaminolevulinate (Metvix, Metvixia)
Description: 2-4 g of cream applied to entire face at Day 0 for 90 minutes without occlusion prior to light treatment. If any actinic keratoses remained after 4 weeks the treatment was repeated at Week 4.
Study NCT00926952 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy (Aktilite)
Description: Device set to 37 J/cm². Red light wavelength is approximately 630 nm.
Study NCT03722797 — intervention group
Intervention type: PROCEDURE
Intervention: Metabolic Cost Testing Procedures
Description: The Oxycon Mobile™Portable VO2 Measurement system will be used to measure VO2 uptake during 2 walking tests. Test order will be randomized.~Treadmill Test: Participants will walk on a treadmill at constant speed, based on the participant's self-selected gait speed, for 2.5 minutes in each stage. Walking will occur at 75% of self-selected gait speed in stage 1, 100% in stage 2, and 125% in stage 3.~Over-ground Test: Participants will walk in an uncarpeted corridor on a course consisting of 2 cones, 20-meters apart. Participants will be instructed to walk at a constant speed for 2.5 minutes in each stage. Instructions will be to walk at their slow speed in stage 1, their usual, comfortable speed in stage 2, and their brisk speed in stage 3.
Study NCT02107729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Large needle gauge lidocaine injection
Description: 21 G
Study NCT02107729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Normal needle gauge lidocaine injection
Description: 23 G
Study NCT02107729 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small needle gauge lidocaine injection
Description: 27 G
Study NCT02434523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
Study NCT02434523 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects in this arm will receive pills composed of only Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
Study NCT00583050 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair
Description: Endovascular exclusion of aneurysm
Study NCT02915354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept must be discontinued. Cotherapy with disease modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs could be continued if maintained at a stable dose for at least 4 weeks.
Study NCT01333137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine and Carboplatin
Description: Gemcitabine 1000 mg/m2/day on Days 1 \& 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
Study NCT01333137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P276-00 along with Gemcitabine and carboplatin
Description: In phase I run in period, P276 00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 \& 8 every 21 days. In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
Study NCT01939405 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: built environment use counseling
Study NCT02753764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD7624
Study NCT02753764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD7624
Study NCT02753764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: oral prednisone 20 mg bid for one week
Study NCT02753764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone
Description: oral prednisone 20 mg bid for one week
Study NCT02753764 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: prednisone
Description: oral prednisone 20 mg bid for one week
Study NCT02753764 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02753764 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04177628 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision making supported by an in-consultation patient decision aid
Description: After having received training in SDM, the doctor will practice SDM supported by an in-consultation PtDA during the consultation with the participant.
Study NCT02347969 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: X34
Description: Dietary supplement named X34
Study NCT03650361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene Gel 0.3%
Description: Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
Study NCT03650361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Differin 0.3% Topical Gel
Description: Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
Study NCT03650361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adapalene Gel 0.3% Vehicle Placebo
Description: Treatment applied as a thin layer of the product to the entire face once a day in the evening for 84 days
Study NCT00953342 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 12 weeks of supervised exercise, 3 x week, 1 hour sessions
Study NCT01534780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glubran
Description: fixation of mesh with Glubran
Study NCT02750605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB
Description: Intervention with drug eluting balloon.
Study NCT02750605 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: POBA
Description: Intervention with old technology as comparison
Study NCT01619020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed Lignans
Description: We will use a specially formulated dietary lignan supplement (Lignan Research Inc., San Diego, CA) as a source of lignans for the lignan challenge in the screening study and as a daily supplement in the intervention. It is a flaxseed extract that contains SDG (269 mg/g; 50 mg/capsule), pinoresinol diglucoside (160 mg/g), and lesser amounts of caffeic (50 mg/g), ferulic (40 mg/g) and coumaric acids (30 mg/g). Lignan capsules and placebo capsules will be prepared by Lignan Research, Inc., a well-established supplement company that follows GMP.
Study NCT01619020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Flaxseed Lignans
Description: We will use a specially formulated dietary lignan supplement (Lignan Research Inc., San Diego, CA) as a source of lignans for the lignan challenge in the screening study and as a daily supplement in the intervention. It is a flaxseed extract that contains SDG (269 mg/g; 50 mg/capsule), pinoresinol diglucoside (160 mg/g), and lesser amounts of caffeic (50 mg/g), ferulic (40 mg/g) and coumaric acids (30 mg/g). Lignan capsules and placebo capsules will be prepared by Lignan Research, Inc., a well-established supplement company that follows GMP.
Study NCT02882880 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Luco Hybrid OSA Appliance
Description: Group 1, initial treatment with the device, reassessed at 14 and 60 days, Group 2, removal of the treatment for 48 hours, to determine if relapse occurs, retested at 60 days with the device (recovery from intervention).
Study NCT02882880 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The Luco Hybrid OSA Appliance
Description: Group 1, initial treatment with the device, reassessed at 14 and 60 days, Group 2, removal of the treatment for 48 hours, to determine if relapse occurs, retested at 60 days with the device (recovery from intervention).
Study NCT01097070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevirimat
Study NCT03180515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activa PC+S Neurostimulator
Description: Activa PC+S Neurostimulator is approved for both aDBS and cDBS paradigms.
Study NCT04317924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyglycolic acid felt
Description: Neoveil is a polyglycolic acid felt that has been shown to decrease the incidence of prolonged air leak after lung resection in Japan.
Study NCT04317924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care after air leak post lung resection
Study NCT03437876 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intestinal microbiota transplant
Description: All participants take 4 times IMT by gastroduodenoscopy with 2-week intervals
Study NCT01851187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: antenatal psychological intervention
Description: emotion management included:~(1) Establish relationship between the health care workers and the pregnant women, (2) Determine training objectives, (3) Guide to practice relaxation training, including imagination and abdominal breathing. (4) Make cognitive adjustment, (5) Relieve anxiety and tension by scene simulation and stimulus exposure. (6) Learn emotional self-regulation, (7) Improve self-efficacy by group interaction. (8) Teach prenatal knowledge ,(9) Guide interactive trainings between pregnant women and their couples; (10) Visit delivery rooms.
Study NCT01851187 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine prenatal care
Description: Prenatal routine inspection included blood pressure, weight, uterine fundal height, abdominal circumference, fetal presentation, fetal position, fetal heart rate and so on.
Study NCT01851187 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine prenatal care
Description: Prenatal routine inspection included blood pressure, weight, uterine fundal height, abdominal circumference, fetal presentation, fetal position, fetal heart rate and so on.
Study NCT00953342 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Standard medical care
Study NCT03988478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Detoxification & psychotherapeutic support
Study NCT02611375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: High-definition transcranial direct current stimulation is applied over the hand area of the primary motor cortex (M1). Parameters= 2mA for 20 minutes. Functional task practice will be completed concurrently with tDCS and for approximate 40 minutes after the stimulation stops.
Study NCT02611375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: peripheral nerve somatosensory stimulation
Description: Electrical stimulation will be applied to the median nerve of the primary hand being trained at parameters that elicit a sensory but not motor response (called peripheral nerve somatosensory stimulation). Stimulation parameters are 100Hz with a 250uS pulse width. Stimulation intensity will vary between 1-10mA per participant. Stimulation will be applied for 1 hour and functional task practice will be completed concurrent with the stimulation.
Study NCT02611375 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: During sham transcranial direct current stimulation (tDCS), a sham tDCS device will be used along with functional task practice. The sham tDCS unit will be used for the first 20 minutes of FTP, followed by an additional 40 minutes of FTP.
Study NCT03558464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Active control: The families living in the control clusters will receive the agriculture-focused package that is already in place in all participating clusters through the 1AF programme. This agriculture focused package consists of: - Agricultural training (every 2 weeks on average) for all - Free to enrol for the following products on credit: o Compost boosters~* Cook stoves o Seeds (onions, maize, indigenous greens, beans) o Maize storage bags o Drying tarps~* Trees o Solar lights o Fertilizer o Actellic dust (insecticide) o Re-usable sanitary pads
Study NCT00445263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIROFIBAN
Description: intravenous infusion
Study NCT00922441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg group
Description: Fimasartan 60 mg
Study NCT00922441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg group
Description: Fimasartan 120 mg
Study NCT00922441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference (Valsartan 80 mg) group
Description: Reference (Valsartan 80 mg)
Study NCT03386617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEPA
Description: Day 1 of each chemotherapy cycle:~1 tablet of NEPA (NETU 300 mg/ PALO 0.50 mg) 1 hour prior to the start of chemotherapy with dexamethasone 12 mg administered orally 30 minutes prior to chemotherapy Days 2 to 3 Dexamethasone. The time and date of intake will be recorded.
Study NCT02690415 — intervention group
Intervention type: PROCEDURE
Intervention: Antibiotics Given
Description: Patients who's treating physician prescribed antibiotics
Study NCT02690415 — intervention group
Intervention type: PROCEDURE
Intervention: Antibiotics not given
Description: Patients who's treating physician did not prescribed antibiotics
Study NCT02617433 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inbody
Description: Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours. After measurement, patient is induced anesthesia. Rocuronium dose is 12mg for male, and 9mg for female.
Study NCT01115283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceptual learning
Description: Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
Study NCT01115283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video Games
Description: Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week).
Study NCT01115283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occlusion therapy
Description: Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).
Study NCT04068285 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Participants will be making aerobic exercise
Study NCT03081143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin\* 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle
Study NCT03081143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle
Study NCT03081143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: 8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle
Study NCT03081143 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 on day 1, 8, 15
Study NCT05992961 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Troponin I
Description: Troponin I were measured 6-12 hours postoperatively and on each of the succeeding four postoperative days for patients operated March 1, 2019, to February 28, 2021.~Patients with increased troponin I levels were assessed regarding symptoms of myocardial ischaemia including electrocardiography. Each patient was individually assessed, and relevant treatment and follow-up were planned in collaboration between surgeons, cardiologists, and anaesthesiologists.
Study NCT00445263 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CORONAROGRAPHY
Description: standard procedure of coronarography
Study NCT02212548 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEG Hydrogel (SpaceOAR)
Description: A single injection of PEG hydrogel (SpaceOAR) through the perineum under transrectal ultrasound guidance while under general anaesthetic.
Study NCT01528943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prostacycline
Description: Continuous infusion peri -and 6 hours postoperatively of prostacycline 1 ng/kg/min
Study NCT01528943 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline
Description: same volume as the group that are allocated to prostacycline
Study NCT03978013 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pomegranate juice
Description: Pomegranate juice
Study NCT03978013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple juice
Description: Apple juice
Study NCT03860116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: APP-based case management service
Description: The intervention consists of 4 parts, educational articles, online communication with case managers, supportive service information and visit reminder. Educational articles are both delivered automatically and retrieved by participants. Online communication can also be initiated by participants and case managers. Case managers are request to respond to questions from participants as well as care about medication taking behaviors of each patients during the first month. Supportive service information, which include time, location and charges of service providers will be retrieved by participants, with reminders of available service information scheduled at the beginning of every month. Visit reminders are scheduled at one week before due date.
Study NCT03860116 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard-of-care followup service
Description: When participants initiate HIV antiretroviral treatment (ART), they receive 20-minute ART-related education from the case managers, and have physical examination including blood test, CD4 count, hepatic and renal function tests. Subsequent visits are scheduled at month 1, 2, 3, 6 and 12. During each visit, pills enough to cover days until the next visit will be distributed. And patients will be asked about their medication adherence, high risk behavior and side effects experienced. Any relevant questions from patients will be answered. Physical tests are also included in the routine of each visits.